Exeltis develops treatments to address unmet medical needs of individuals, families, and healthcare professionals. It has nearly 4,000 professionals in more than 40 countries.
Coverage
6 items
Dilafor signs deal with Exeltis for tafoxiparinglobenewswire.com/news-release/2026/01/21/3223003/0/en/Karolinska-Development-s-portfolio-company-Dilafor-signs-binding-term-sheet-with-Exeltis-for-a-license-agreement-regarding-tafoxiparin.html
Dilafor signs a binding term sheet granting Exeltis an exclusive semi-global license to tafoxiparin for priming of labor. Exeltis funds pivotal trials under the agreement, which covers the drug’s use in labor priming and establishes a licensing arrangement between the two companies.
Theranexus grants Exeltis exclusive rights to commercialize TX01 for Gaucher disease and Niemann-Pick type C in Europe, the UK, Latin America, and the Middle East. The licensing deal covers two rare neurological diseases, and Theranexus shares rose 34% following its announcement.
Agile Therapeutics completes its acquisition by Insud Pharma, combining with Exeltis USA. Under the deal, Agile Therapeutics shareholders receive $1.52 per share, and the transaction has an enterprise value of approximately $45 million.
Exeltis USA launched Blues Away, an over-the-counter, three-day dietary shake designed to support postpartum mood in new mothers experiencing postpartum blues. The product is backed by data published in eClinicalMedicine.
